These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 12867058)
1. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Raben D; Helfrich B; Ciardiello F; Bunn PA Lung Cancer; 2003 Aug; 41 Suppl 1():S15-22. PubMed ID: 12867058 [TBL] [Abstract][Full Text] [Related]
6. ZD1839 (Iressa): what's in it for the patient? Natale RB; Zaretsky SL Oncologist; 2002; 7 Suppl 4():25-30. PubMed ID: 12202785 [TBL] [Abstract][Full Text] [Related]
7. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial. Price N; Belani C Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012 [No Abstract] [Full Text] [Related]
8. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Pao W; Miller VA; Kris MG Semin Cancer Biol; 2004 Feb; 14(1):33-40. PubMed ID: 14757534 [TBL] [Abstract][Full Text] [Related]
9. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. Hirsh V BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538 [TBL] [Abstract][Full Text] [Related]
11. EGFR inhibitors: clinical results. De Marinis F; Nelli F; D'Auria G Suppl Tumori; 2002; 1(6):S5-6. PubMed ID: 12658893 [No Abstract] [Full Text] [Related]
12. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Engelman JA; Jänne PA; Mermel C; Pearlberg J; Mukohara T; Fleet C; Cichowski K; Johnson BE; Cantley LC Proc Natl Acad Sci U S A; 2005 Mar; 102(10):3788-93. PubMed ID: 15731348 [TBL] [Abstract][Full Text] [Related]
13. Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies. Manegold C Adv Exp Med Biol; 2003; 532():247-52. PubMed ID: 12908563 [TBL] [Abstract][Full Text] [Related]
14. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145 [TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836 [TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. Harichand-Herdt S; Ramalingam SS Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731 [TBL] [Abstract][Full Text] [Related]
17. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer. Wang H; Fei Z; Jiang H J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172 [TBL] [Abstract][Full Text] [Related]
18. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers. Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140 [TBL] [Abstract][Full Text] [Related]
20. The role of EGFR inhibitors in nonsmall cell lung cancer. Ciardiello F; De Vita F; Orditura M; Tortora G Curr Opin Oncol; 2004 Mar; 16(2):130-5. PubMed ID: 15075904 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]